Idelalisib Patent Expiration
Idelalisib is used for disrupting leukocyte function, specifically for the treatment of CLL, FL, or SLL, and in combination with rituximab. It was first introduced by Gilead Sciences Inc
Idelalisib Patents
Given below is the list of patents protecting Idelalisib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zydelig | US9469643 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | Sep 02, 2033 | Gilead Sciences Inc |
| Zydelig | US10730879 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | Mar 05, 2033 | Gilead Sciences Inc |
| Zydelig | US8865730 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | Mar 05, 2033 | Gilead Sciences Inc |
| Zydelig | US9492449 | Therapies for hematologic malignancies | Mar 11, 2030 | Gilead Sciences Inc |
| Zydelig | USRE44638 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | Aug 05, 2025 | Gilead Sciences Inc |
| Zydelig | USRE44599 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | Jul 21, 2025 | Gilead Sciences Inc |
| Zydelig | US8980901 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | May 12, 2025 | Gilead Sciences Inc |
| Zydelig | US9149477 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | May 12, 2025 | Gilead Sciences Inc |
| Zydelig | US6800620 | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr 24, 2021
(Expired) | Gilead Sciences Inc |
| Zydelig | US6949535 | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr 24, 2021
(Expired) | Gilead Sciences Inc |
| Zydelig | US8138195 | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr 24, 2021
(Expired) | Gilead Sciences Inc |
| Zydelig | US8492389 | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr 24, 2021
(Expired) | Gilead Sciences Inc |
| Zydelig | US8637533 | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr 24, 2021
(Expired) | Gilead Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Idelalisib's patents.
Latest Legal Activities on Idelalisib's Patents
Given below is the list recent legal activities going on the following patents of Idelalisib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 May, 2024 | US9492449 |
| Expire Patent Critical | 22 Apr, 2024 | US8138195 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Apr, 2024 | US9469643 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jan, 2024 | US10730879 |
| Maintenance Fee Reminder Mailed Critical | 06 Nov, 2023 | US8138195 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Mar, 2023 | US9149477 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8980901 |
| Correspondence Address Change Critical | 26 Apr, 2022 | US10730879 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Apr, 2022 | US8865730 |
| Expire Patent Critical | 07 Mar, 2022 | US8637533 |
Idelalisib's Family Patents
